On Jul. 24, 2018, Hangzhou Sumgen Biotech Co., Ltd. (hereinafter “Sumgen Biotech”) announced that IND (Investigational New Drug) application of their proprietary recombinant anti-PD-1 fully human monoclonal antibody injection was filed to CDE (Center for Drug Evaluation in China) of NMPA (China National Medical Products Administration) (acceptance number: CXSL1800084 G).
On Jul. 24, 2018, Sumgen Biotech announced that IND (Investigational New Drug) application of their proprietary recombinant anti-PD-1 fully human monoclonal antibody injection was filed to CDE (Center for Drug Evaluation in China) of NMPA (China National Medical Products Administration) (acceptance number: CXSL1800084 G). This antibody drug is the first national class I new drug with independent intellectual property rights developed by Sumgen Biotech, which can be used for the clinical treatment of various malignancies in the future.
Copyright Rm. 301, F3, Building C, Block 2, No. 688, Bin'an Road, Changhe Zhejiang ICP Filing No. 18039044
